SCHEMBL29788043

SCHEMBL29788043

COC(=O)c1ccc(-c2ccccc2OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.56
TSHR P16473 1/20 0.55
PTPN1 P18031 3/20 0.54
PTPRC P08575 2/20 0.54
PTPRF P10586 1/20 0.54
CDC25B P30305 1/20 0.54
SLC6A3 Q01959 3/20 0.53
SLC6A4 P31645 2/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MAPT P10636 2/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
VDR P11473 1/20 0.49
FFAR2 O15552 1/20 0.49
PTGS1 P23219 1/20 0.49
XDH P47989 1/20 0.49
CASP3 P42574 1/20 0.49
RAB9A P51151 1/20 0.49
SENP8 Q96LD8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2050621 1.00 EGFR (0.56) EGFRTSHRPTPN1PTPRCPTPRF
SCHEMBL21246919 0.86 PTPRC (0.51) TSHRPTPN1PTPRCMAPTLMNA
SCHEMBL6535966 0.85 ADORA3 (0.50) EGFRTSHRPTPN1PTPRCPTPRF
SCHEMBL3508583 0.85 POLB (0.55) TSHRPTPN1PTPRCSLC6A3MAPT
SCHEMBL1222758 0.84 RXRA (0.58) EGFRCA1CA2FFAR2XDH
SCHEMBL12189290 0.84 L3MBTL1 (0.60) PTPN1PTPRCMAPTLMNASMN1; SMN2
SCHEMBL15999083 0.84 PTPN1 (0.52) EGFRTSHRPTPN1PTPRCPTPRF
SCHEMBL4146550 0.84 MAPT (0.55) PTPN1CA1CA2MAPTLMNA
SCHEMBL27708108 0.84 EGFR (0.71) EGFRTSHRPTPN1PTPRCPTPRF
SCHEMBL5944253 0.83 HDAC6 (0.60) CA1CA2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119013017-A Pharmaceutical composition for treating cancer comprising an anticancer agent and a novel compound having an inhibitory activity on prostaglandin E2 receptor 治纳辅医药科技有限公司 2024-11-22 CN disclosed
CN-114773249-B Compounds, pharmaceutical compositions and methods for treating inflammatory diseases 艾匹克治疗公司 2024-08-16 CN disclosed
WO-2023158221-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS 주식회사 카나프테라퓨틱스 2023-08-24 WO disclosed
CN-114773249-A Compounds, pharmaceutical compositions and methods for treating inflammatory diseases 艾匹克治疗公司 2022-07-22 CN disclosed